Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.
Also called NCT02492620
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT02492620
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02492620. Randomized; no masking; primary purpose treatment. Start 2015-03 (registry gives no type); primary completion 2017-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D
- Acronym
- 05D
- Condition
- Chronic Kidney Disease
- Condition
- Hyperphosphatemia
- Condition
- Iron Deficiency Anemia
- Condition
- Renal Insufficiency
- Intervention (Drug)
- Ferric Citrate
- Lead sponsor
- Denver Nephrologists, P.C.
- Collaborator
- Keryx Biopharmaceuticals
Record details
- Record id
cardio:ct-nct02492620- Content hash
414ef28831a2dd22c141711c331a386a435e038bba61d187227d4b4813cc257a